To test whether patients enrolled in our study accumulated BTK mutations after ibrutinib treatment, we performed targeted sequencing of BTK, focusing on codons 316 and 481, two residues frequently mutated in patients with CLL who had become resistant to ibrutinib treatment [22]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.